Boston Scientific keeps innovating

Article Excerpt

There’s little doubt that the developing world’s aging population will continue to spend more on medical services for years to come. Topmedical device makers are well positioned to capture a share of that increased spending. We continue to see attractive, long-term investment opportunities for our subscribers among the top device manufacturers. That includes Boston Scientific; we recommend the stock as a Power Buy. BOSTON SCIENTIFIC CORP., $36.03, is a buy. The company (New York symbol BSX; TSINetwork Rating: Average) (www.bostonscientific.com; Shares outstanding: 1.4 billion; Market cap: $50.3 billion; No dividends paid) develops and markets medical devices used in minimally invasive procedures. Its products are used for angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, and many other surgical procedures. It generates 58% of its sales in the U.S. and 42% internationally. In the three months ended March 31, 2022, Boston Scientific’s revenues rose 10.0%, to $3.03 billion from $2.75 billion a year earlier. Like other industry suppliers, Boston Scientific was hurt by deferred non-elective surgeries…

You are trying to access subscriber-only content.

To read this article, you may subscribe or sign in.
If you are already a subscriber, log in here.

If you wish to become a subscriber, click here. Or you may enjoy access to all our publications when you become a Member of Pat McKeough's Inner Circle Pro.